Cedars-Sinai Technology Ventures has had 114 patents issued for the fiscal year 2021 and has 511 active technologies under development, as of July 2021
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
It will be the first and only global office for traditional medicine in the world
Routine tests undertaken by women dropped by 35% in 2020
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Dr Ratna Puri from Sir Ganga Ram Hospital, Delhi is the Chairperson of the expert committee.
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
